Favorable legislation and recent commercial successes have stimulated growing interest in the discovery of novel orphan drugs. However, there are many strategic considerations that are peculiar to the R&D process for diseases of low prevalence.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions